Ampersand Capital Partners Acquires Vibalogics to Advance Viral Vector Therapies for Cancer and Genetic Disorders

VCBeat (WeChat ID: vcbeat) has learned that Vibalogics GmbH was recently acquired by the private equity firm Ampersand Capital Partners. The specific transaction amount was not disclosed.

Following the acquisition, with the support of Ampersand Capital Partners, Vibalogics GmbH has been able to strengthen its comprehensive capabilities to meet the substantial unmet demand for viral vector development in the healthcare industry.

Vibalogics GmbH, established in 2002 and headquartered in Lower Saxony, Germany, is a contract development and manufacturing organization (CDMO). The company is dedicated to providing process development, cGMP manufacturing, product finishing, and other services to biopharmaceutical companies engaged in the development of oncolytic virus therapies, gene therapies, and vaccines.

Vibalogics GmbH operates a manufacturing plant in Cuxhaven, Germany. The facility covers an area of 2,500 square meters and features four independent GMP production suites, a 600-square-meter cleanroom, and a state-of-the-art automated facility monitoring system. The facility is reported to be fully compliant with international GMP standards.

At its inception, Vibalogics GmbH aimed to produce veterinary products based on viral vector platforms and engage in contract development and manufacturing by hiring industry experts. In 2007, the company shifted its primary focus to the human health sector while continuing to offer a range of veterinary products to its customers. Currently, the company employs 50 people and has expanded its business operations to Europe, the United States, and the Asia-Pacific region.

Ampersand Capital Partners, established in 1988, is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. Ampersand maintains offices in Boston, Massachusetts, and Amsterdam, the Netherlands. Leveraging its unique private equity and operational expertise, Ampersand has built a diverse portfolio of companies in the healthcare industry, including Avista Pharma Solutions, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories.

Stefan Beyer, CEO of Vibalogics GmbH, stated: “Leveraging our partnership with Ampersand Capital Partners, we are able to expand our operations in the United States and Europe, further strengthen our process development and GMP manufacturing capabilities, and solidify our existing position in the biologics sector. Additionally, this partnership will help us develop innovative therapies, thereby significantly improving treatment outcomes for patients with cancer and genetic disorders.”

David Anderson, General Partner at Ampersand Capital Partners, stated, “Vibalogics GmbH is one of the leaders in the biologics sector. We have extensive investment experience in the field of contract manufacturing for viral vectors, and we look forward to collaborating with the company to accelerate the development of cutting-edge therapies for patients.”

(Compiled by Jiao Yanli)